Skip Ribbon Commands
Skip to main content

The Aerosol & Mucosal ​Vaccination community is comprised of individuals from different Institutions worldwide and includes the following members:​​

Dr Helen McShane

Co-Chair

​Helen McShane is currently Director of the NIHR Oxford Biomedical Research Centre; Professor of Vaccinology at Oxford University; Deputy Head (Translation and Personnel), Medical Sciences Division; and an Honorary Consultant physician in HIV and GU medicine.

Helen obtained an intercalated BSc in 1988, followed by a degree in medicine in 1991 (both University of London). In 1997 She was awarded an MRC Clinical Training Fellowship to undertake a PhD with Adrian Hill in Oxford, and was later awarded a PhD in 2001 (University of London). In 2001 she was awarded a Wellcome Clinician Scientist Fellowship, allowing her to complete her clinical training and subsequently awarded a CCST in HIV and GU Medicine in 2003. In 2005 and 2010, she was awarded a Wellcome Senior Clinical Research Fellowship. She currently holds a Wellcome Trust Investigator Award.

Since 2001, Helen has lead a TB vaccine research group at the University of Oxford. She led the development of MVA85A, the first new TB vaccine candidate to enter efficacy testing. Current areas of focus include the development of controlled human mycobacterial challenge models, aerosol delivery of vaccines and immunomonitoring in clinical trials. She collaborates with several research groups across Africa in TB vaccine clinical trials.

Dr Rajko Reljic

Co-Chair

Members

Dr Steffen Stenger

Steffen Stenger is Professor of Medicine, specialized in Medical Microbiology, Infection Control and Hospital Hygiene. He is Director of the laboratory for Medical Microbiology and responsible for the implementation of antibiotic stewardship at the University Hospital Ulm. As such he is directly involved in the diagnosis and treatment of patients with tuberculosis. Over the past 20 years Dr. Stenger´s laboratory focused on understanding effector mechanisms of the human immune system against Mycobacterium tuberculosis. Major focus of the research was the identification and functional characterization of antimicrobial T cell subsets. Together with Dr. Modlin he participated in the identification of granulysin as an antimicrobial effector molecule of human CD8+ cytotoxic T cells. Translational studies involving large, well-defined patient cohorts demonstrated that granulysin-expressing effector memory T cells contribute to protection in human tuberculosis. He is member of the steering committee of the “TBornotTB” consortium funded by the German Ministry for Research to set up the first comprehensive German cohort of tuberculosis patients and their close contacts to identify risk factors for transmission of disease. His current scientific focus is to understand local immunity in tuberculosis at the site of disease. This includes studies on the interaction of human cells obtained from bronchoalveolar lavage with virulent Mycobacterium tuberculosis as well as the identification and functional optimization of antimicrobial peptides from human lung. Steffen served as founder and co-chair of the CTVD research community “Aerosol & Mucosal Vaccination” until 2018.

Dr Aurelio Bonavia

Dr Warwick Britton

Dr Philip Kuehl

Dr Troy Randall

Dr Chad Roy

Dr Zhou Xing